🔥Telegram İfşa

A fun debate with Kanya Rajangam at #IO360nyc today. Go #gdtcells! Thanks to Michael Kalos , Kate Woda and Dan Chen Chen for the invitation! #adoptive #immunotherapy #cancer lnkd.in/eUkgYXEW

Proud of the team we've built @IN8bio! We've made tremendous progress in the clinic for #gdTcells. Look out for our data updates at medical meetings this fall! $INAB #IN8bio #gbm #celltherapy #leukemia #aml

Thanks to our old friends Mara Goldstein at #Mizuho and Brad Loncar at @BiotechTVHQ for following our story and supporting us over the years. We’re looking forward to providing an update tomorrow morning (12/12). Stay tuned! $INAB #GDTcells #ASH2023 #CancerZero

Thanks Brad Loncar for the kind words. It's a difficult path, but well worth it to help #cancer patients. Come checkout our poster presentation (abstract: 4853) tonight at #ASH2023!

TV and the media often portray #CEOs as symbols of #success and glamour. Yet seldom showcased are the relentless challenges - the constant travel, lack of sleep, jet lag, stress and endless meetings in dreary conference rooms. But what makes it all truly worthwhile? It's the

Yesterday, we proudly announced long-term PFS data in our Ph 1 trial of INB-100 allogeneic #gdTcells for #Leukemia at #ASH24. Read more: bit.ly/4iveWCU. Our entire team in collaboration with KU Cancer Center have worked hard to continue to advance this trial, bringing a

Wrapping up #JPM2025, the mood seemed quite dour, especially on the buy side. However, starting the week on the oncology panel for #BiotechShowcase, I'm optimistic! Many are advancing innovative science to make a difference for cancer patients. Thanks to the great panel members

GO IRISH!

So proud of the IN8bio team and truly honored to partner with Dr. McGuirk and the whole @KUCancerCenter team. Together we are working towards our mission of achieving Cancer Zero and making a difference for leukemia patients!

Yesterday we presented at TD Cowen—excited to unveil INB-600, our next-gen γδ T cell engager! • TCEs are a billion-dollar success in immunotherapy (J&J, Roche) • INB-619 not only engages γδ T cells but expands them for a stronger, longer-lasting immune response • Designed for

I wanted to express my sincere gratitude to Asthika Goonewardene at Truist for an exceptional dinner last night, and a thank you to Dr. Georg Schett for his captivating talk at this year’s #IO360 conference. I eagerly anticipate the incredible opportunities that lie ahead!

A big thank you to #IO360, Kate Woodard, Axel Hoos and Valerie Bowling for giving me the opportunity to share why I think IN8bio is taking a fundamentally different approach in the race to bring a new therapy to autoimmune diseases. By my last count, over 45 programs are

Thanks to EmpoweredPatient for inviting me on her Empowered Patient Podcast to talk about IN8bio’s mission and how gamma-delta T cells are one of the most exciting frontiers in immunotherapy. We’re building smarter, and potentially safer and more effective therapies for cancer &

Exciting progress on our preclinical pipeline presented this week at AACR2025. Our lead T cell engager candidates, INB-619 (targeting CD19) and INB-633 (targeting CD33), have shown potent anti-cancer activity with some distinct advantages! They effectively eliminated cancer

When we founded IN8bio, the idea was simple but ambitious: bring smarter, safer cell therapies to patients who need better options. Glioblastoma is one of the deadliest cancers, with virtually no progress in over two decades. Many told us not to bother because it was too hard,

Exciting data from our Phase 1 INB-200 program presented in an oral session this weekend at ASCO2025! I heard great feedback from KOLs across the country as we try to make a real impact for these patients with GBM. Please join us on a conference call at 8:30am EDT as we review

Exactly! This is the biology we’re building @IN8bio around. So much potential!